AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26447154
Drug: d6-RRR-α-tocopherol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d6-RRR-α-tocopherol (15 mg) with nonfat milk (0.2 g fat)
Trial: 26447154
Drug: d6-RRR-α-tocopherol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d6-RRR-α-tocopherol (15 mg) with reduced-fat milk (4.8 g fat)
Trial: 26447154
Drug: d6-RRR-α-tocopherol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d6-RRR-α-tocopherol (15 mg) with whole milk (7.9 g fat)
Trial: 23233252
Drug: Topical pazopanib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pazopanib 0.5% for 3 weeks
Trial: 16496249
Drug: Dorzolamide +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide + Timolol Fixed Combination (DTFC)
Trial: 10699771
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) with meperidine as additional analgesia, self-administered by patients.
Trial: 10699771
Drug: Standard sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sedation with meperidine and midazolam administered by the anesthesiologist.
Trial: 8408793
Drug: Methylprednisolone aceponate
RxNorm normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone aceponate (MPA) 0.1% ointment
Trial: 8408793
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate ointment
Trial: 2960897
Drug: t-PA (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t-PA (80 to 100 mg intravenously over three hours)
Trial: 25602175
Drug: Ranolazine 375
RxNorm normalized name: Ranolazine 375 mg prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine 375 mg bid
Trial: 20828645
Drug: Ranolazine 500
RxNorm normalized name: ranolazine 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine 500 mg bid
Trial: 25602175
Drug: Ranolazine 750
RxNorm normalized name: Ranolazine 750 mg prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine 750 mg bid
Trial: 25602175
Drug: Combined ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined ranolazine 500 mg and 750 mg
Trial: 20001868
Drug: Dienogest (DNG)
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dienogest (DNG) 2 mg/day
Trial: 20001868
Drug: Intranasal buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal buserelin acetate
Trial: 20001868
Drug: Norethisterone acetate
RxNorm normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethisterone acetate 10 mg/day
Trial: 16893642
Drug: Conventionally dosed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally dosed chemotherapy (group A)
Trial: 10460994
Drug: 17alpha-hydroxyprogesterone caproate
RxNorm normalized name: 17alpha-Hydroxyprogesterone hexanoate
DrugBank: Hydroxyprogesterone caproate (DB06789)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17alpha-hydroxyprogesterone caproate (17-OHPc) at a dosage of 341 mg every 3 days
Trial: 10460994
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution as placebo every 3 days
Trial: 31957794
Drug: Telephone outreach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone outreach call plus invitation to engage in mental health tailored telephone counseling and assistance obtaining nicotine replacement therapy
Trial: 31421395
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (136.6 mg aglycone equivalence)
Trial: 20566178
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment based on severity: OSDI (mild) = carboxymethylcelullose, OSDI (moderate) = hidroxypropylmethylcelullose, OSDI (severe) = polyethyleneglycol, OSDI (very severe) = polyethyleneglycol + cyclosporine A 0.05%.
Trial: 20566178
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment administered based on severity of symptoms.
Trial: 12028164
Drug: tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine ER 4 mg once daily (n = 507)
Trial: 10215688
Drug: Ketamine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.4 mg/kg combined with midazolam 0.05 mg/kg
Trial: 10215688
Drug: Pethidine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine 1.0 mg/kg
Trial: 10215688
Drug: Ketamine hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine hydrochloride 4.0 mg/kg (oral)
Trial: 10215688
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (oral)
Trial: 8570775
Drug: Naltrexone (NTX)
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone (NTX) at a daily oral dose of 0.5 mg/kg/day
Trial: 2223424
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of carbamazepine
Trial: 2223424
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with zopiclone and carbamazepine
Trial: 453259
Drug: Laminaria placed
RxNorm normalized name: Laminaria digitata preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laminaria placed at the time of the abortifacient injection (Group II, N = 23)
Trial: 453259
Drug: Laminaria placed
RxNorm normalized name: Laminaria digitata preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laminaria placed 4 hours prior to injection (Group III, N = 29)
Trial: 453259
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional therapy (Group I, N = 28)
Trial: 31838255
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (110 ≤ SBP < 130 mmHg)
Trial: 31838255
Drug: Mild treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild treatment (130 ≤ SBP < 150 mmHg)
Trial: 26175420
Drug: Antiosteoporotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiosteoporotic drugs
Trial: 16881774
Drug: Pharmacotherapy for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy for bipolar disorder (duration up to 28 months)
Trial: 11260171
Drug: 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg of zinc sulphate orally
Trial: 11260171
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of zinc sulphate orally
Trial: 11260171
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg of zinc sulphate orally
Trial: 8427168
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg 3 times daily
Trial: 29921575
Drug: Shen-Shuai-Ning (SSN)
RxNorm normalized name: Ren shen
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shen-Shuai-Ning (SSN) granule, 5 g three times daily for 12 weeks
Trial: 29921575
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (baseline medications and dialysis prescriptions)
Trial: 26162647
Drug: Infliximab (IFX)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (IFX) 5 mg/kg
Trial: 24613110
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human interleukin 11, 1.5 mg subcutaneously
Trial: 20378829
Drug: TU-100 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TU-100 2.5 g tid
Trial: 20378829
Drug: TU-100 5
RxNorm normalized name: Tu Mu Xiang
DrugBank: Inula helenium root (DB14350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TU-100 5 g tid
Trial: 20378829
Drug: TU-100 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TU-100 7.5 g/day
Trial: 12625641
Drug: Treadmill therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treadmill therapy with partial body weight support (BWS)
Trial: 22394493
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Group Therapy (CBGT); 12-session protocol
Trial: 18853113
Drug: Shugan Jianpi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shugan Jianpi Granule (SJG) 24 g three times a day
Trial: 18853113
Drug: Shugan Jianpi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shugan Jianpi Granule (SJG) 24 g three times a day + Smecta 15 g three times a day
Trial: 16447880
Drug: Shenqi Fuzheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi Fuzheng injection (SFI) 100 ml, administered in 5% glucose solution 500 ml for intravenous dripping, once a day for 20 days
Trial: 16447880
Drug: Nitroglycerine injection
RxNorm normalized name: nitroglycerin Injection
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerine injection 10 mg, administered in 5% glucose solution 500 ml for intravenous dripping, once a day for 20 days
Trial: 7750591
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (10 mg/d)
Trial: 7857113
Drug: Daily application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily application of strong sunscreen
Trial: 7049029
Drug: Tetracycline hydrochloride,
RxNorm normalized name: Tetracycline Hydrochloride, Ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline hydrochloride, 500 mg orally four times daily for 7 days
Trial: 7049029
Drug: Rosaramicin, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosaramicin, 250 mg orally four times daily for 7 days
Trial: 31257264
Drug: MFGM 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFGM 1.0 g + glucosamine 1.5 g
Trial: 26262771
Drug: Eplerenone 25
RxNorm normalized name: eplerenone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 25 mg
Trial: 26262771
Drug: Eplerenone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (all doses)
Trial: 26262771
Drug: Eplerenone (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (multiple doses)
Trial: 25249056
Drug: Small Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small Group (SG) treatment (12 members/group)
Trial: 25249056
Drug: Large Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large Group (LG) treatment (30 members/group)
Trial: 19691545
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted cognitive‐behavior therapy (CBT)
Trial: 15190831
Drug: Viagra combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viagra combined with behavior therapy
Trial: 15190831
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy alone (control group)
Trial: 7741071
Drug: DES (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DES (500 mg daily injection) for 7 days before LH-RH analogue (3.6 mg of Zoladex depot)
Trial: 7741071
Drug: DES (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DES (500 mg injection) for 7 days prior to LH-RH analogue, plus additional DES injection for 7 days
Trial: 7741071
Drug: DES (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DES (500 mg injection) for 7 days simultaneously with LH-RH analogue
Trial: 7741071
Drug: DES (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DES (500 mg injection) for 7 days prior to LH-RH analogue, plus additional DES injection for 3 days
Trial: 1970298
Drug: Bisoprolol 10
RxNorm normalized name: bisoprolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 10 mg daily (increased to 20 mg if necessary)
Trial: 1970298
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg daily (increased to 100 mg if necessary)
Trial: 31775686
Drug: Sulfadoxine-Pyrimethamine (IPTp-SP)
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-Pyrimethamine (IPTp-SP) administered during pregnancy
Trial: 31775686
Drug: Direct Observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Observed Therapy (DOT) for SP administration
Trial: 28267474
Drug: Azimilide 75
RxNorm normalized name: Azimilide
DrugBank: Azimilide (DB04957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azimilide 75 mg daily
Trial: 27852711
Drug: Medication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication treatment (MT) plus percutaneous transluminal angioplasty and stenting (PTAS)
Trial: 27852711
Drug: Medication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication treatment (MT) alone
Trial: 27852711
Drug: Medication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication treatment (MT) plus PTAS
Trial: 25118680
Drug: Cemented shaft
RxNorm normalized name: Cacao seed oil, fermented
DrugBank: Cocoa butter (DB11086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemented shaft implants
Trial: 23963102
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg/day plus Tolterodine 2 mg (twice a day)
Trial: 23963102
Drug: Tolterodine 2
RxNorm normalized name: tolterodine 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 2 mg (twice a day)
Trial: 17445639
Drug: No medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medical treatment (control group)
Trial: 8085623
Drug: Indomethacin 2
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 2 mg/kg
Trial: 23356392
Drug: 125 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 µg fluticasone dipropionate and 25 µg salmeterol, two actuations twice daily, by either separate or combination ICS/LABA inhalers
Trial: 8128175
Drug: Cisapride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (5 mg three times daily)
Trial: 8128175
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg three times daily)
Trial: 163937
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with 0.3 percent 'Neutralrot' eye drops and radiation with daylight lamp HPR 125 W.
Trial: 163937
Drug: Intramuscular inoculation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular inoculation with Interferonogen.
Trial: 26087637
Drug: diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac sodium 100 mg/day
Trial: 26087637
Drug: Alflutop injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alflutop injection 1 ml per day for 20 days, then 2 ml intraarticular twice weekly in the following month
Trial: 26087637
Drug: diacerein (diaflex,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diacerein (diaflex, 'Rompharm Company') 50 mg twice daily for 3 months
Trial: 23921483
Drug: Chromium-enriched yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromium-enriched yeast (100 μg daily for 2 weeks)
Trial: 23921483
Drug: Chromium-enriched yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromium-enriched yeast (200 μg daily for 6 weeks)
Trial: 23921483
Drug: Chromium-enriched yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromium-enriched yeast (100 μg and 200 μg daily)
Trial: 21519733
Drug: Glutamine group
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine group (50 g L-glutamine, 400 mL evening drink and 200 mL 2 hours before anesthesia)
Trial: 21519733
Drug: Carbohydrate group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate group (12.5% maltodextrine, 400 mL evening drink and 200 mL 2 hours before anesthesia)
Trial: 21519733
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (water, 400 mL evening drink and 200 mL 2 hours before anesthesia)
Trial: 11724442
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to IFN-gamma
Trial: 11724442
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to TNF-alpha
Trial: 8492200
Drug: Ibuprofen-codeine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen-codeine (400 mg ibuprofen + 60 mg codeine)
Trial: 20597358
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (received one session of psycho-education about self-complexity and kept daily records for one week)
Trial: 17121048
Drug: Acupuncture in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture in Siguan points combined with intravenous midazolam injection
Trial: 17121048
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam injection
Trial: 12541156
Drug: DCLHb (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCLHb (up to 1000 ml of a 10% diaspirin cross‐linked hemoglobin solution)
Trial: 8445202
Drug: Methylprednisolone (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (initial bolus of 30 mg/kg followed by infusion of 5.4 mg/kg/h over 23 hours)
Trial: 3528240
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics plus elastic support bandages
Trial: 29550766
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg with loading dose (LD)
Trial: 29550766
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg with loading dose (LD)
Trial: 29550766
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg without loading dose (LD)
Trial: 24504006
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg twice-daily for 12 months
Trial: 22146609
Drug: Conventional walking
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional walking treatment (CWT)
Trial: 16243131
Drug: All light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All light doses (70, 100, 140 J/cm2)
Trial: 26197801
Drug: Blended learning
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended learning approach (combination of face-to-face and online/mobile learning)
Trial: 16890114
Drug: EC-MPS 1,080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC-MPS 1,080 mg twice daily
Trial: 16890114
Drug: MMF 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 1,500 mg twice daily
Trial: 15292101
Drug: 4 LNG
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 LNG rods (75 mg each) followed by 500 mg of TU by IM injection every 8 weeks for 24 weeks (Group I)
Trial: 15292101
Drug: 4 LNG
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 LNG implants followed by 1000 mg of TU by IM injection every 8 weeks for 24 weeks (Group II)
Trial: 15292101
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of TU by IM injection every 8 weeks for 24 weeks (Group III)
Trial: 9444444
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of lubeluzole (1-hour intravenous infusion)
Trial: 9444444
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of lubeluzole (1-hour intravenous infusion)
Trial: 9444444
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of lubeluzole (1-hour intravenous infusion)
Trial: 9444444
Drug: Lubeluzole (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubeluzole (various doses)
Trial: 29956042
Drug: Optimum post-infarction
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimum post-infarction treatment (Control group)
Trial: 18599019
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac 0.4% plus prednisolone acetate 1% QID